The classification of acute myeloid leukemia (AML) has evolved from the primarily morphologic and cytochemical system of the early French-American-British Cooperative Group (FAB) proposal 1,2 to systems that consider the results of cytogenetic studies. 3, 4 Recurring balanced translocations, particularly t(8;21), t(15;17), inv(16)/t(16;16), and 11q23 translocations, represent a substantial percentage of cytogenetic abnormalities in AML. These aberrations constitute 34% to 47% of pediatric 5-7 and 21% to 28% of adult 6, [8] [9] [10] AML cytogenetic abnormalities. Additional abnormalities, including trisomies, deletions, and complex karyotypes, contribute to another large percentage of adult AMLs 6,10,11 and show overlap with cases of myelodysplasia. The detection of these various cytogenetic abnormalities in AML is known to have prognostic significance, 5-12 but many of them do not correlate well with FAB classification disease groups. Despite the detection of significant cytogenetic abnormalities in many AML cases, a substantial subset of cases show no karyotypic abnormality. 13 Cryptic translocations are present in some of these cases, and other molecular genetic abnormalities presumably are present in the leukemic cells of these patients.
A b s t r a c t
, t (8;21) , inv (16) /t (16;16) , and 11q23 showed significant differences in 5- The classification of acute myeloid leukemia (AML) has evolved from the primarily morphologic and cytochemical system of the early French-American-British Cooperative Group (FAB) proposal 1, 2 to systems that consider the results of cytogenetic studies. 3, 4 Recurring balanced translocations, particularly t(8;21), t(15;17), inv(16)/t (16;16) , and 11q23 translocations, represent a substantial percentage of cytogenetic abnormalities in AML. These aberrations constitute 34% to 47% of pediatric [5] [6] [7] and 21% to 28% of adult 6, [8] [9] [10] AML cytogenetic abnormalities. Additional abnormalities, including trisomies, deletions, and complex karyotypes, contribute to another large percentage of adult AMLs 6, 10, 11 and show overlap with cases of myelodysplasia. The detection of these various cytogenetic abnormalities in AML is known to have prognostic significance, [5] [6] [7] [8] [9] [10] [11] [12] but many of them do not correlate well with FAB classification disease groups. Despite the detection of significant cytogenetic abnormalities in many AML cases, a substantial subset of cases show no karyotypic abnormality. 13 Cryptic translocations are present in some of these cases, and other molecular genetic abnormalities presumably are present in the leukemic cells of these patients.
Some karyotype abnormalities in AML are associated with characteristic morphologic and/or immunophenotypic findings. These include leukemias with neoplastic promyelocytes showing loss of HLA-DR with t(15;17) and its variants, [14] [15] [16] CD19+/CD34+ myeloid cells with abundant and distinctive granules of t(8;21), [17] [18] [19] [20] and abnormal eosinophils of inv(16) AML. [21] [22] [23] [24] The morphologic detection of multilineage dysplasia often correlates with older age and the presence of complex karyotypes, monosomies, or trisomies, but also may occur in the absence of cytogenetic abnormalities. 13, [25] [26] [27] Several studies suggest that the presence of multilineage dysplasia is associated with a worse prognosis in AML. 25, [27] [28] [29] Despite the correlation between acute promyelocytic leukemia (FAB type M3) and t (15;17) , and acute myelomonocytic leukemia with eosinophilia (FAB type M4Eo) and inv(16)/t(16;16), the FAB classification does not incorporate cytogenetic results into its system. In addition, the presence of multilineage dysplasia is not considered part of that classification. These parameters, however, are major elements of the recently published World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, 3 which includes AML, as well as in the recently proposed Realistic Pathologic Classification (RPC) of AML. 4 These classification systems also differ from the FAB classification by lowering the blast cell count to 20% or more for most cases of AML and not requiring a specific blast cell count in the presence of recurring cytogenetic abnormalities.
The present study was undertaken to evaluate the prognostic significance of the recently proposed classifications systems, the FAB classification, and a risk-group cytogenetic stratification. Specific elements of interest were the impact of lowering the blast cell count to 20% in AML and the significance of subgroups with recurrent cytogenetic abnormalities and multilineage dysplasia. The significance of morphologic and cytochemical subclassification of AMLs without recurrent cytogenetic abnormalities or multilineage dysplasia also was evaluated.
Materials and Methods
This retrospective study included 300 cases of AML or refractory anemia with excess blasts in transformation diagnosed based on a blast cell count of 20% or more at the City of Hope National Medical Center, Duarte, CA, between January 1990 and October 2000. Cases were included in the study if overall survival information was available and if original diagnostic pathology material was available for review. Morphologic review on all cases was performed by one of the authors (D.A.A.), and bone marrow aspirate material or peripheral blood smears containing blast cells were required for all cases. Cytochemical results and results of immunophenotyping studies also were reviewed. Based on the slide review, cases were classified using the published criteria of the FAB, 2 WHO, 3 and RPC 4 classifications with correlation with available presentation cytogenetic studies. Cytogenetic results were available for 228 cases. Cytogenetic risk group stratification also was performed by one of the authors (M.L.S.), using criteria similar to those previously described. 10 Cases were considered to be favorable or low risk in the presence of t(8;21), inv (16) Five-year Kaplan-Meier survival estimates were tested using the Mantel-Haenszel (log-rank) test. 30 The 95% confidence intervals (CIs) on the Kaplan-Meier estimates were calculated using a logit transformation of the Greenwood estimate of the variance. The Pearson χ 2 test 31 was used to test for differences in the proportion of cytogenetic abnormalities among different groups within the FAB classification. All P values are 2-sided, and values less than .05 were considered significant (SAS/STAT Software, Changes and Enhancements, Release 8.02, SAS Institute, Cary, NC).
Results
The cases included 154 males and 146 females with mean and median ages of 40.6 and 41 years, respectively (range, 1-76 years). Thirteen patients were younger than 18 years. The overall 5-year survival for the group was 35.8% with a 95% CI of 30.3% to 41.4%. The median follow-up for patients who were alive (n = 112) was 70.6 months (range, 9.2-127.2 months) and for patients who died (n = 188) was 12.0 months (range, 0.1-58.9 months).
Classification Groups
The breakdowns for the FAB, WHO, and RPC classifications are given in ❚Table 1❚, ❚Table 2❚, and ❚Table 3❚. Numeric differences between the groups are due to differences in diagnostic criteria for each classification. In the FAB classification, 21 (7.0%) were unclassified owing to insufficient cytochemical results. Only 228 cases were classified using the WHO criteria, owing to the requirement for cytogenetic studies for classification. In the therapy-related AML category of the WHO classification, 2 cases were not further classified owing to a combination of previous therapy or radiation therapy. In the RPC classification, there were 34 AML cases, not otherwise specified (NOS), with monocytic or myelomonocytic features by cytochemistry. Cytogenetic risk-group stratification included 67 low risk (29.4%), 100 intermediate risk (43.9%), and 61 high risk (26.8%).
Impact of Lowering the Blast Cell Count for AML to 20%
No significant difference in overall survival was identified when cases with 20% or more blasts but fewer than 30% blasts were compared with all AML cases with 30% or more blasts; with AML cases, NOS [those without recurring cytogenetic abnormalities t(8;21), inv(16), or t(15;17) or multilineage dysplasia]; or with cases of AML with multilineage dysplasia or therapy-related AML. Sixteen of the cases with fewer than 30% blast cells were classified as AML with multilineage dysplasia, 4 as therapy-related AML, and 1 as AML with 11q23 abnormalities. Three cases did not have cytogenetic studies but had morphologic features of AML with abnormal eosinophils suggestive of inv(16) (1 case) or myelodysplasia-associated AML (2 cases) in the RPC classification. The overall survival of the AML group with low blast cell count was essentially identical to the group AML with multilineage dysplasia. The 5-year survival for AMLs with 20% or more to less than 30% blast cells (n = 24) was 18% (95% CI, 2%-34%). Comparison with the survival for other groups was as follows: 37.3% (95% CI, 31.5%-43.3%; P = .1603) for all AML cases with more than 30% blast cells (n = 276); 39.8% (95% CI, 30.4%-49.3%; P = .1347) for AML cases, not otherwise categorized with more than 30% blast cells (n = 109); and 19.3% (95% CI, 11.1%-27.6%; P = .4904) for AML cases with multilineage dysplasia or AML cases that were treatment related (n = 114). ❚Figure 1❚ illustrates the similarity in survival between the low blast cell count group and the AML cases with multilineage dysplasia or therapy-related AML.
FAB Classification Groups
FAB subgroups with 10 or more cases were compared with all other cases for 5-year survival differences ❚Table 4❚. FAB types M0, M3, and M4Eo differed significantly from the other groups. The M0 cases were reclassified in the WHO classification into AML, not otherwise categorized (minimally differentiated type; 3 cases); AML with multilineage dysplasia (5 cases); and AML with 11q23 abnormalities (3 cases). The remaining cases did not have cytogenetic abnormalities but were classified as AML, NOS (4 cases); AML with multilineage dysplasia (1 case); and therapyrelated AML (2 cases) in the RPC classification. For FAB type M0 vs non-M0 types, the frequency of high-risk cytogenetics (50% vs 18.4%, respectively; P = .0036) and the frequency of 11q23 abnormalities (17% vs 2.8%, respectively; P = .0222) were significantly higher in the M0 group. No differences in the frequency of previous therapy or multilineage dysplasia were found between the AML-M0 and the non-M0 cases.
Significance of Recurrent Cytogenetic Abnormality Subgroups
The 5-year overall survival rates for the groups with recurrent cytogenetic abnormalities were as follows: t(8;21), 40% (n = 16; 95% CI, 15%-66%); t(15;17), 60% (n = 20; 95% CI, 38%-81%); inv(16)/t(16;16), 61% (n = 31; 95% CI, 43%-78%); and 11q23 abnormalities, 12% (n = 11; 95% CI, 0%-34%) (overall P = .0266). The survival differences of these categories are illustrated in ❚Figure 2❚.
Significance of Morphologic Detection of Multilineage Dysplasia
Of the cases studied, 106 were AML with morphologic features of multilineage dysplasia, including 31 with preexisting myelodysplasia. Eight cases of therapy-related AML also were identified. No significant differences in overall survival were identified between cases of therapy-related disease, AML arising from myelodysplasia, and AML with associated myelodysplastic changes and no history of myelodysplasia (P = .9823) ❚Figure 3❚. This combined group (n = 114), however, had a lower 5-year overall survival (18.4%; 95% CI, 11.1%-25.7%) compared with cases of AML without associated myelodysplastic changes (n = 186; 5-year survival, 46.7%; 95% CI, 39.3%-54.1%; P < .0001).
This difference remained significant when compared with AML, NOS, which excludes the favorable prognostic groups of t(8;21), inv (16) , and t(15;17) AML (n = 109; 5-year survival, 39.8%; 95% CI, 30.4%-49.3%; P = .0014).
Lack of Significance of Subclassification of AML, Not Otherwise Categorized/NOS
The 109 cases in the RPC AML, NOS group and the 70 cases in the WHO AML, not otherwise categorized group were evaluated to attempt to assess the significance of subcategories of each. Cytochemical evidence of monocytic or myelomonocytic differentiation (n = 34; 5-year survival, 41%; 95% CI, 24%-58%) did not identify a significant diagnostic group when compared with cases without such differentiation (n = 74; 5-year survival 38%; 95% CI, 27%-50%; P = .7945).
Comparisons of overall survival for the WHO, not otherwise categorized groups were made for AML without maturation (n = 19; 5-year survival, 25%; 95% CI, 5%-45%), AML with maturation (n = 21; 5-year survival, 41%; 95% CI, 20%-63%), and acute myelomonocytic leukemia (n = 16; 5-year survival, 25%; 95% CI, 2%-49%) and the other AML, not otherwise categorized cases. There were insufficient cases in the remaining groups for statistical comparison. No significant differences in survival were identified by separating these 3 subcategories of AML, not otherwise categorized (P = .7876).
Comparison of Diagnostic Groups by Treatment
In an attempt to evaluate some treatment differences and the role of different treatments in the differences in outcome of the major classification groups, cases were separated in the RPC classification into AML, NOS (n = 109; 5-year Significant survival differences (P < .0001) were recognized using this separation. These groups then were compared by therapy type, with broad categories of allogeneic transplantation (n = 144), autologous transplantation (n = 71), and no transplantation (n = 79). Details of the overall 5-year survival for each group are given in ❚Table 5❚. The disease groups, however, remained significantly distinct with each treatment type (P = .0175 for autologous transplantation; P = .0233 for allogeneic transplantation; P = .006 for no transplantation).
Clinically Significant Disease Groups
❚Table 6❚ shows a modification of the RPC classification, based on the significant disease groups of this study. These include AMLs with evidence of t(8;21), t(15;17), or inv(16)/t(16;16); AML with multilineage dysplasia or therapy-related AML; and AML, NOS. ❚Figure 4❚ and ❚Figure 5❚ illustrate the overall survival of the significant disease groups in the RPC and WHO classifications.
Discussion
The FAB classification of AML has been the major system used by hematopathologists for more than 20 years. This system was useful in that it provided structured criteria for the diagnosis of a variety of morphologic and cytochemical subtypes of AML. The present study, however, indicates that the majority of categories in this system do not delineate significant disease groups, based on overall survival. The only significant FAB groups identified were M0, M3, and M4Eo. The significance of M3 and M4Eo are not surprising because of the high correlation of these subgroups with t(15;17) and inv(16)/t(16;16), respectively. These cytogenetic abnormalities are known to be associated with significantly improved survival with current therapies compared with other AML types. 12, 32, 33 The significantly worse prognosis of AML-M0 compared with other AMLs in the present study seems to be related to its high association with the poor-prognosis cytogenetic groups of AML, including AML with 11q23 abnormalities. The recently proposed AML classification systems include categories that encompass the significant FAB disease groups, and the remaining FAB groups seem to be of little, if any, significance. Several studies have demonstrated the impact of specific cytogenetic abnormalities on survival in AML, with t(15;17) and its variants, t(8;21), inv(16)/t(16;16), and abnormalities involving 11q23 being the most common. 6, 10, 12 The present study confirms the significance of these abnormalities, with t(15;17) and inv(16)/t(16;16) AMLs having a more favorable prognosis, t(8;21) conferring an intermediate prognosis, and 11q23 abnormalities associated with a generally poor prognosis. Because AMLs with 11q23 abnormalities do not have sufficiently specific morphologic and immunophenotypic findings to suggest this abnormality and because of the reported variability in prognosis based on the 11q23-translocation partner, these leukemias were not designated as a subtype in the Realistic Pathologic Classification. 4 However, the prognostic importance of 11q23 abnormalities indicates that the detection of such abnormalities should be noted in an amended pathology report for a complete diagnosis. Continued studies to evaluate the prognostic significance of other balanced translocations in AML are needed, and additional subgroups of AML with recurrent cytogenetic abnormalities should be considered as additions to any future classification systems.
The impact of multilineage dysplasia in AML also has been studied previously. The frequency of trilineage dysplasia in de novo AML was reported as 11.6% in a series of 336 cases by Goasguen and colleagues 25 and 12% in a series of 162 cases by Tamura and associates. 29 The current definition of AML with multilineage dysplasia requires dysplastic changes in only 2 cell lines, accounting for the higher percentage (38%) of cases in that category in the present study. 3, 4 Goasguen et al 25 found that the presence of dysgranulopoiesis was associated with a significant decrease in the ability to achieve a complete remission, while Tamura et al 29 found the presence of trilineage dysplasia to be associated with lower disease-free survival. Dysplastic changes of granulocytes and megakaryocytes were associated with a worse event-free survival in a series of 102 patients with AML by Gahn et al. 28 The present study suggests that the less rigid criteria of multilineage dysplasia (2 cell lines involved rather than 3) retain clinical significance, with a significantly worse overall survival observed in these patients. In addition, the present study suggests that AMLs with multilineage dysplasia behave in a similar manner whether they arise from myelodysplasia or are de novo.
Both the WHO and RPC classifications include a lowering of the blast cell count for acute leukemia to 20%, 34 showed a similar outcome for patients treated with AML-type therapy with lower blast cell counts compared with patients with 30% or more blasts. The present study supports the lowering of the blast cell count for a diagnosis of AML. The majority of cases with 20% to 30% blast cells were classified as AML with multilineage dysplasia or therapy-related AML, and patients had a virtually identical overall survival to the AML groups with 30% or more blasts. After removal of cases with multilineage dysplasia or recurring cytogenetic abnormalities, few cases remained in many of the disease subgroups of the WHO classification of AML, not otherwise categorized. Of those with sufficient numbers for analysis, no significance could be determined for such subdivisions of this category. However, taken as a whole, the AML, not otherwise categorized of the WHO classification and AML, NOS of the RPC classification were of intermediate risk compared with AMLs with favorable recurrent cytogenetic abnormalities and AML with multilineage dysplasia or therapy-related AML (Figure 4 ). Therefore, these general categories seem to be significant, but there seems to be little relevance to subdividing them based on cytochemical findings. Future subdivision of this group based on molecular genetic differences may be of value as more recurring abnormalities are defined.
Although the same therapy regimen was not used in all cases in the present study, the major disease groups remained significantly different when subsets of cases in general treatment groups were analyzed. These groups included different types of transplantation (allogeneic and autologous) and cases without transplantation. A similar study of a large number of patients treated in an identical manner would be needed to definitely determine the significance of each of the proposed disease groups. However, such a study would be difficult to undertake owing to the recognized advantages of certain treatment strategies that are common for specific leukemia types, such as the core binding factor leukemias and acute promyelocytic leukemia. 12, 32, 35, 36 The present study suggests that lowering the blast cell count for AML to 20% is justified, with most cases added by this criterion having an overall survival that is similar to AML with multilineage dysplasia. The detection of recurrent cytogenetic abnormalities and multilineage dysplasia provides useful prognostic information in the classification of AML. Six significant disease types were confirmed in the present study: (1) AML with t(15;17), (2) AML with inv(16), (3) AML with t(8;21), (4) AML with 11q23, (5) AML with multilineage dysplasia or therapy-related AML, and (6) AML, NOS. Diseases such as acute megakaryoblastic leukemia without multilineage dysplasia, which occurs more often in infants, also may be of significance. However, de novo acute megakaryoblastic leukemia was not sufficiently represented in the present study for any conclusion to be made. Proposed subclassifications of the broad category of AMLs without multilineage dysplasia or recurrent cytogenetic abnormalities do not seem appropriate at present, particularly based on cytochemical evidence of monocytic or myelomonocytic differentiation. The identification of additional cytogenetic or molecular genetic abnormalities in AML should permit the future identification of other clinically significant disease subgroups in the AML with multilineage dysplasia and the AML, NOS disease groups. A revision of the RPC that reflects the present findings is provided in Table 6 . This revised approach continues 
